Hematologic toxicity in radioimmunotherapy: Dose-response relationships for I-131 labeled antibody therapy

Cancer Biotherapy and Radiopharmaceuticals

Volumn 17, Issue 4, 2002, Pages 435-443

  O'Donoghue, Joseph A ^a   Baidoo, NanaEfua ^a   Deland, Devie ^a   Welt, Sydney ^a   Divgi, Chaitanya R ^a   Sgouros, George ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Absorbed dose; Dose response; Radioimmunotherapy; Thrombocytopenia; Toxicity

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN FRAGMENT; IMMUNOGLOBULIN G; IODINE 131;

ARTICLE; BETA RADIATION; BLOOD TOXICITY; DIAGNOSTIC ACCURACY; DOSE RESPONSE; DOSIMETRY; HUMAN; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; THROMBOCYTOPENIA; VALIDATION PROCESS;

EID: 0036381362     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497802760363222     Document Type: Article

References (21)

1. Junghans RP, Sgouros G, Scheinberg DA. Antibodybased Immunotherapies for Cancer. In: Chabner B and Longo DL, Eds. Cancer Chemotherapy and Biotherapy: Principles and Practice, 2nd Edition, Lippincott; 1996: 655-689.
2. Lim S, DeNardo GL, DeNardo DA, O'Donnell RT, Yuan A, DeNardo SJ. Prediction of myelotoxicity using semi-quantitative marrow image scores. J Nucl Med 1997; 38: 1749-1753.
3. DeNardo DA, DeNardo GL, O'Donnell RT, et al. Imaging for improved prediction of myelotoxicity after radioimmunotherapy. Cancer 1997; 80(Suppl): 2558-2566.
4. Siegel JA, Lee RE, Pawlyk DA, Horowitz JA, Sharkey RM, Goldenberg DM. Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy. Int J Rad Appl Instrum [B] 1989; 16: 553-559.
5. Macey DJ, DeNardo SJ, DeNardo GL, DeNardo DA, Shen S. Estimation of radiation absorbed doses to the red marrow in radioimmunotherapy. Clin Nucl Med 1995; 20: 117-125.
6. Bigler RE, Zanzonico PB, Leonard R, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. In: Schlafke-Stelson AT, Watson EE, Eds. Proceedings of the fourth international dosimetry symposium. Oak Ridge, TN:CONF-851113-(DE86010102); 1985: 535-544.
7. Siegel JA, Wessels BW, Watson EE, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunocon Radiopharm 1990; 3: 213-233.
8. Johnson TK, Gonzalez R, Kasliwal RK, et al. Distribution of a breast-directed I-131-radiolabeled monoclonal antibody in blood and bone marrow: Implications for radiation immunotherapy. Radiology 1992; 182:107-114.
9. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: Theoretical considerations. J Nucl Med 1993; 34: 689-694.
10. Breitz HB, Fisher DR, Wessels BW. Marrow toxicity and radiation absorbed dose estimates from rhenium186-labeled monoclonal antibody. J Nucl Med 1998; 39: 1746-1751.
11. Blumenthal RD, Alisauskas R, Lew W, Juweid M, Goldenberg DM. Predictive markers of recovery from myelosuppressive therapy [abstract]. Cancer Biother Radiopharm 1998; 13: 308.
12. Sgouros G, Divgi CR, Scott AM, Williams J, Larson SM. Hematologic toxicity in radioimmunotherapy: An evaluation of different predictive measures [abstract]. J Nucl Med 1996; 37: 43P-44P.
13. Wiseman GA, White CA, Stabin M, et al, Phase I/II Y90-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med 2000; 27: 766-777.
14. Juweid ME, Sharkey RM, Behr T, et al. Radioimmunotherapy of patients with small-volume tumors using iodine-131-labeled anti-CEA monoclonal antibody NP-4 F(ab′)2. J Nucl Med 1996; 37: 1504-1510.
15. Juweid M, Sharkey RM, Behr T, et al. Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies. J Nucl Med 1996; 37: 905-911.
16. Meredith RF, Khazaeli MB, Plott WE, et al. Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer. J Nucl Med 1992;33:23-29.
17. Sgouros G, Deland D, Loh AC, Divgi CR, Larson SM. Marrow and whole-body absorbed dose vs. marrow toxicity following 131I-G250 antibody therapy in patients with renal-cell carcinoma [abstract]. J Nucl Med 1997; 38: 252P.
18. Stewart JS, Hird V, Snook D, et al. Intraperitoneal radioimmunotherapy for ovarian cancer: pharmacokinetics, toxicity, and efficacy of I-131 labeled monoclonal antibodies. Int J Radiat Oncol Biol Phys 1989; 16:405-413.
19. Snyder WS, Ford MR, Warner GG, Watson EB. "S," absorbed dose per unit cumulated activity for selected radionuclides and organs. MIRD Pamphlet No. 11, Revised. New York: Society of Nuclear Medicine; 1975.
20. O'Donoghue JA, Anwar K, Kavanagh KR, Larson SM, Old LJ, Divgi CR. Pharmacokinetic-based treatment planning for fractionated radioimmunotherapy of renal cell cancer with [131I]-labeled monoclonal antibody cG250 [abstract]. J Nucl. Med 1999; 40: 326P.
21. DeNardo DA, DeNardo GL, Yuan A, et al. Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies. J Nucl Med 1996; 37: 1970-1975.